Henry Schein, Inc. $HSIC Shares Bought by Swedbank AB

Swedbank AB raised its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 1.0% during the fourth quarter, HoldingsChannel.com reports. The firm owned 1,312,312 shares of the company’s stock after buying an additional 12,741 shares during the period. Swedbank AB’s holdings in Henry Schein were worth $99,185,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. CYBER HORNET ETFs LLC acquired a new stake in shares of Henry Schein during the 2nd quarter valued at approximately $25,000. MUFG Securities EMEA plc acquired a new stake in shares of Henry Schein during the 2nd quarter valued at approximately $27,000. Flagship Harbor Advisors LLC acquired a new stake in shares of Henry Schein during the 4th quarter valued at approximately $30,000. Steph & Co. acquired a new stake in shares of Henry Schein during the 4th quarter valued at approximately $52,000. Finally, Tema Etfs LLC acquired a new stake in shares of Henry Schein during the 4th quarter valued at approximately $56,000. 96.62% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Kurt P. Kuehn sold 2,844 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $78.96, for a total transaction of $224,562.24. Following the completion of the transaction, the director owned 15,420 shares of the company’s stock, valued at $1,217,563.20. This trade represents a 15.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Philip A. Laskawy sold 2,844 shares of the firm’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $80.36, for a total value of $228,543.84. Following the transaction, the director directly owned 21,961 shares of the company’s stock, valued at $1,764,785.96. This represents a 11.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 105,911 shares of company stock valued at $8,574,982. Company insiders own 0.89% of the company’s stock.

Analyst Upgrades and Downgrades

HSIC has been the topic of several research reports. Leerink Partners reissued a “market perform” rating on shares of Henry Schein in a research report on Monday, March 9th. Weiss Ratings reissued a “hold (c+)” rating on shares of Henry Schein in a research report on Monday, May 4th. Wall Street Zen lowered Henry Schein from a “strong-buy” rating to a “buy” rating in a research report on Sunday, April 26th. Mizuho dropped their price target on Henry Schein from $88.00 to $82.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Finally, Barrington Research set a $97.00 price target on Henry Schein and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Six research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $86.83.

Henry Schein Trading Up 1.0%

NASDAQ:HSIC opened at $74.21 on Friday. Henry Schein, Inc. has a 1 year low of $61.94 and a 1 year high of $89.29. The stock has a market cap of $8.45 billion, a price-to-earnings ratio of 22.42, a PEG ratio of 1.86 and a beta of 0.82. The business has a fifty day moving average of $74.34 and a 200-day moving average of $75.62. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.75 and a current ratio of 1.36.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.12. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The company had revenue of $3.37 billion during the quarter, compared to analysts’ expectations of $3.34 billion. During the same quarter in the prior year, the business posted $1.15 earnings per share. The company’s revenue for the quarter was up 6.3% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Equities analysts predict that Henry Schein, Inc. will post 5.31 earnings per share for the current year.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.